A Randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans

Charles H. Hennekens, Wendy R. Schneider, Alex Pokov, Scott Hetzel, David Demets, Victor Serebruany, Henning Schröder

Research output: Contribution to journalArticle

Abstract

Background: We performed the first test in humans of whether aspirin at clinically relevant doses increases nitric oxide (NO) formation. Methods: Seventy primary prevention patients with metabolic syndrome were randomly assigned to 81 mg, 162.5 mg, 325 mg, 650 mg, or 1300 mg aspirin daily for 12 weeks to test changes in heme oxygenase (HO-1), a downstream target of NO formation and asymmetrical dimethylarginine (ADMA), a competitive inhibitor of NO synthase. Findings: For HO-1, the mean was 29.37 nanograms per milliliter at baseline and 57.45 at 12 weeks giving a mean ratio (MR) of 1.96 (P

Original languageEnglish (US)
Pages (from-to)344-348
Number of pages5
JournalJournal of Cardiovascular Pharmacology and Therapeutics
Volume15
Issue number4
DOIs
StatePublished - Dec 2010
Externally publishedYes

Fingerprint

Aspirin
Nitric Oxide
Heme Oxygenase-1
Primary Prevention
Nitric Oxide Synthase
dimethylarginine

Keywords

  • atherosclerosis
  • cardiovascular disease
  • endothelium
  • thrombosis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Hennekens, C. H., Schneider, W. R., Pokov, A., Hetzel, S., Demets, D., Serebruany, V., & Schröder, H. (2010). A Randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans. Journal of Cardiovascular Pharmacology and Therapeutics, 15(4), 344-348. https://doi.org/10.1177/1074248410375091

A Randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans. / Hennekens, Charles H.; Schneider, Wendy R.; Pokov, Alex; Hetzel, Scott; Demets, David; Serebruany, Victor; Schröder, Henning.

In: Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 15, No. 4, 12.2010, p. 344-348.

Research output: Contribution to journalArticle

Hennekens, CH, Schneider, WR, Pokov, A, Hetzel, S, Demets, D, Serebruany, V & Schröder, H 2010, 'A Randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans', Journal of Cardiovascular Pharmacology and Therapeutics, vol. 15, no. 4, pp. 344-348. https://doi.org/10.1177/1074248410375091
Hennekens, Charles H. ; Schneider, Wendy R. ; Pokov, Alex ; Hetzel, Scott ; Demets, David ; Serebruany, Victor ; Schröder, Henning. / A Randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans. In: Journal of Cardiovascular Pharmacology and Therapeutics. 2010 ; Vol. 15, No. 4. pp. 344-348.
@article{6fa0d95317984a9bbc5f0e510f800f71,
title = "A Randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans",
abstract = "Background: We performed the first test in humans of whether aspirin at clinically relevant doses increases nitric oxide (NO) formation. Methods: Seventy primary prevention patients with metabolic syndrome were randomly assigned to 81 mg, 162.5 mg, 325 mg, 650 mg, or 1300 mg aspirin daily for 12 weeks to test changes in heme oxygenase (HO-1), a downstream target of NO formation and asymmetrical dimethylarginine (ADMA), a competitive inhibitor of NO synthase. Findings: For HO-1, the mean was 29.37 nanograms per milliliter at baseline and 57.45 at 12 weeks giving a mean ratio (MR) of 1.96 (P",
keywords = "atherosclerosis, cardiovascular disease, endothelium, thrombosis",
author = "Hennekens, {Charles H.} and Schneider, {Wendy R.} and Alex Pokov and Scott Hetzel and David Demets and Victor Serebruany and Henning Schr{\"o}der",
year = "2010",
month = "12",
doi = "10.1177/1074248410375091",
language = "English (US)",
volume = "15",
pages = "344--348",
journal = "Journal of Cardiovascular Pharmacology and Therapeutics",
issn = "1074-2484",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - A Randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans

AU - Hennekens, Charles H.

AU - Schneider, Wendy R.

AU - Pokov, Alex

AU - Hetzel, Scott

AU - Demets, David

AU - Serebruany, Victor

AU - Schröder, Henning

PY - 2010/12

Y1 - 2010/12

N2 - Background: We performed the first test in humans of whether aspirin at clinically relevant doses increases nitric oxide (NO) formation. Methods: Seventy primary prevention patients with metabolic syndrome were randomly assigned to 81 mg, 162.5 mg, 325 mg, 650 mg, or 1300 mg aspirin daily for 12 weeks to test changes in heme oxygenase (HO-1), a downstream target of NO formation and asymmetrical dimethylarginine (ADMA), a competitive inhibitor of NO synthase. Findings: For HO-1, the mean was 29.37 nanograms per milliliter at baseline and 57.45 at 12 weeks giving a mean ratio (MR) of 1.96 (P

AB - Background: We performed the first test in humans of whether aspirin at clinically relevant doses increases nitric oxide (NO) formation. Methods: Seventy primary prevention patients with metabolic syndrome were randomly assigned to 81 mg, 162.5 mg, 325 mg, 650 mg, or 1300 mg aspirin daily for 12 weeks to test changes in heme oxygenase (HO-1), a downstream target of NO formation and asymmetrical dimethylarginine (ADMA), a competitive inhibitor of NO synthase. Findings: For HO-1, the mean was 29.37 nanograms per milliliter at baseline and 57.45 at 12 weeks giving a mean ratio (MR) of 1.96 (P

KW - atherosclerosis

KW - cardiovascular disease

KW - endothelium

KW - thrombosis

UR - http://www.scopus.com/inward/record.url?scp=78651331360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651331360&partnerID=8YFLogxK

U2 - 10.1177/1074248410375091

DO - 10.1177/1074248410375091

M3 - Article

C2 - 20938039

AN - SCOPUS:78651331360

VL - 15

SP - 344

EP - 348

JO - Journal of Cardiovascular Pharmacology and Therapeutics

JF - Journal of Cardiovascular Pharmacology and Therapeutics

SN - 1074-2484

IS - 4

ER -